Catalyst Event
Alteogen Inc (196170) · Other
From KRX Bio Technology Transfer Index (KBIOTT)
3/25/2026, 12:00:00 AM
Alteogen's exclusive license agreement with Biogen for its ALT-B4 technology on March 25, 2026, is expected to have a >10% price impact due to the significant deal size of 867.6 billion KRW, scheduled.
Korean Translation
2026년 3월 25일 알테오젠의 바이오젠 대상 ALT-B4 기술 독점 라이선스 계약 체결은 8,676억 원 규모의 대형 계약으로 10% 이상의 주가 영향이 예상됨.
Related Recent Events
Hanmi Pharm Co Ltd (128940) · Other
Annual general shareholder meeting on 2026-03-31 to vote on the appointment of a new CEO and board members amid a management dispute; high impact estimated due to potential governance shift scheduled.
3/31/2026, 12:00:00 AM
LigaChem Biosciences Inc (141080) · Other
The 20th Annual General Shareholders' Meeting on March 31, 2026, to approve financial statements and appoint a new director (Low importance estimated as standard annual meetings without major corporate changes usually have minimal price impact) scheduled
3/31/2026, 12:00:00 AM
Daewoong Pharmaceutical Co Ltd (069620) · Other
The 25th Annual General Meeting of Shareholders is scheduled for March 26, 2026. Low importance is estimated as the agenda items are routine and unlikely to cause significant price volatility scheduled.
3/26/2026, 12:00:00 AM
Chong Kun Dang Pharm Co (185750) · Other
The 13th Annual General Meeting of Shareholders is scheduled.
3/26/2026, 12:00:00 AM
AprilBio Co Ltd (397030) · Other
The 13th Annual General Meeting of Shareholders was held on March 25, 2026. Resolutions passed included the approval of the 2025 financial statements, amendments to the articles of incorporation, and the granting of stock options.
3/25/2026, 12:00:00 AM
GC Cell Corporation (144510) · Earnings Release
Reported FY2025 results on March 24, 2026, with a significant net loss of KRW 273.5 billion, primarily due to a one-time, non-cash goodwill impairment charge of approximately KRW 220 billion from a past merger. High importance is assigned due to the magnitude of the net loss relative to revenue, which is expected to cause a price impact exceeding 10%.
3/24/2026, 12:00:00 AM